Peony Yu - FibroGen Chief Medical Officer

FGEN Stock  USD 1.17  0.10  7.87%   

Executive

Dr. K. Peony Yu, M.D., is Chief Medical Officer of the Company. She served as our Vice President of Clinical Development from December 2008 until April 2016 when she was promoted to Chief Medical Officer. Dr. Yu brings to us expertise in design and execution of all phases of clinical development programs, including clinical and regulatory strategy, interactions with regulatory authorities in the United States and European Union, as well as experience with successful leadership of clinical teams. Prior to joining us, Dr. Yu was Vice President of Clinical Research at Anesiva, Inc., where she was responsible for management of clinical research, statisticsdata management, clinical operations, and medical affairsmedical information for all clinical programs, including the latestage clinical development and approval of Zingo, a drugdevice combination for pain management. Prior to Anesiva, Dr. Yu was Director, Clinical Development at ALZA Corporation where she was Global Clinical Lead for IONSYS, a drugdevice combination for postoperative pain, and led a successful New Drug Application resubmission with the U.S. Food and Drug Administration and multiple interactions with European regulatory authorities resulting in marketing approval in 25 European countries. Prior to ALZA, Dr. Yu held previous posts at Pain Therapeutics, Inc. and at Elan Pharmaceuticals since 2016.
Age 54
Tenure 8 years
Address 409 Illinois Street, San Francisco, CA, United States, 94158
Phone415 978 1200
Webhttps://www.fibrogen.com
Yu received a BS degree in Chemical Engineering and a medical degree both from the University of California, Davis, followed by residency training at Stanford Medical School.

FibroGen Management Efficiency

The company has return on total asset (ROA) of (0.3554) % which means that it has lost $0.3554 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1579) %, meaning that it created substantial loss on money invested by shareholders. FibroGen's management efficiency ratios could be used to measure how well FibroGen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to grow to -0.64. In addition to that, Return On Capital Employed is likely to grow to -1.24. At this time, FibroGen's Total Assets are very stable compared to the past year. As of the 19th of April 2024, Non Current Assets Total is likely to grow to about 146.7 M, while Other Assets are likely to drop 0.95.
The company currently holds 170.46 M in liabilities with Debt to Equity (D/E) ratio of 0.89, which is about average as compared to similar companies. FibroGen has a current ratio of 2.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist FibroGen until it has trouble settling it off, either with new capital or with free cash flow. So, FibroGen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like FibroGen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for FibroGen to invest in growth at high rates of return. When we think about FibroGen's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Josie YangAVROBIO
N/A
Arturo MolinaSutro Biopharma
59
Mario OrlandoGossamer Bio
N/A
John SullivanBolyaiHepion Pharmaceuticals
76
Catriona YaleAkero Therapeutics
52
Lionel CarnotMerus BV
49
Xiaolin WangRevolution Medicines
53
Ellen BrougMerus BV
N/A
Ravi UpasaniBiomea Fusion
N/A
Robert MBAVerastem
N/A
Luisa SalterCidGossamer Bio
59
Lauren MBADay One Biopharmaceuticals
48
Kirsten DupuisAVROBIO
N/A
Amy WiremanBiomarin Pharmaceutical
N/A
Jonathan DayBiomarin Pharmaceutical
N/A
Caryn PetersonGossamer Bio
65
Steven JDAVROBIO
62
Scott BillerAgios Pharm
62
John CavanHepion Pharmaceuticals
66
Michael HowellZura Bio Limited
47
Janet GraesserVaxcyteInc
N/A
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Fibrogen Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 566 people. FibroGen (FGEN) is traded on NASDAQ Exchange in USA. It is located in 409 Illinois Street, San Francisco, CA, United States, 94158 and employs 486 people. FibroGen is listed under Biotechnology category by Fama And French industry classification.

Management Performance

FibroGen Leadership Team

Elected by the shareholders, the FibroGen's board of directors comprises two types of representatives: FibroGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of FibroGen. The board's role is to monitor FibroGen's management team and ensure that shareholders' interests are well served. FibroGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, FibroGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Kearns, Independent Director
Kirk MBA, Chief Officer
Rahul Kaushik, Technical Development
Jorma Routti, Independent Director
Mr JD, Chief Officer
Jeffrey Edwards, Director
Barry Berkowitz, Founder
James Schoeneck, Independent Director
David DeLucia, Vice Relations
Toshinari Tamura, Independent Director
Jeffrey Henderson, Director
K Yu, Vice President - Clinical Development
Peony Yu, Chief Medical Officer
Gerald Lema, Director
Juan Graham, Chief Officer
Roberto Rosenkranz, Independent Director
Thomas Neff, Founder, Chairman and CEO
Enrique Conterno, CEO Director
Frank Valone, Chief Medical Officer
Kalevi Kurkijarvi, Independent Director
Christine Chung, Senior Operations
Suzanne Blaug, Independent Director
Thane Wettig, CEO Director
Maykin Ho, Independent Director
Elias Kouchakji, Drug Devel
Rory Riggs, Independent Director
Julian Stern, Corporate Secretary, Director, Member of Audit Committee and Member of Compensation Committee
KinHung Yu, Chief Medical Officer
Karen Bergman, Vice President Investor Relations and Corporate Communications
Tricia Stewart, Chief Officer
Pat Cotroneo, CFO, Vice President - Finance
MPH MD, Ex Officer
John Hunter, Chief Officer

FibroGen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is FibroGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether FibroGen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of FibroGen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fibrogen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fibrogen Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.
Note that the FibroGen information on this page should be used as a complementary analysis to other FibroGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for FibroGen Stock analysis

When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Bonds Directory
Find actively traded corporate debentures issued by US companies
Is FibroGen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.536
Earnings Share
(2.92)
Revenue Per Share
1.518
Quarterly Revenue Growth
(0.21)
Return On Assets
(0.36)
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.